Why BGPT?
logo

Verify the Claims

Check manuscripts against claims linked to experiments, exact reported results, and cited sources β€” flag what the data does not support.Know what the science actually supports before you trust the answer.

Press Enter ↡ to review claims


     Quick Explanation



    The paper reports FANCI stop-gain variant rs121918164 in 3/101 Polish top-elite athletes but absent from 1,899 comparators; however, Bonferroni-adjusted p = 0.069 fails genome-wide significance, no physiological data on carriers exist, and the authors themselves concede chance cannot be excluded, so the "beneficial pathogenic variant" hypothesis remains an unproven, exploratory observation.


     Long Explanation



    The Core Finding

    Whole-genome sequencing of 101 Polish top-elite male athletes (53 speed, 48 endurance; age 23.5 Β± 5.9 y) identified the putatively pathogenic FANCI nonsense variant rs121918164 (c.3853C>T, p.Arg1285*) in three unrelated carriers (two speed, one endurance), while TaqMan screening found zero carriers among 890 national-elite athletes, 1,009 sedentary controls, and 1,222 Polish reference genomes . Kinship analysis (max pairwise kinship 0.0026) rules out recent shared ancestry .

    Statistical Reality Check

    The unadjusted Fisher's exact p vs gnomAD non-Finnish Europeans is 1.57Γ—10⁻⁷, but the authors' own conservative Bonferroni correction over 443,769 high-confidence loss-of-function variants yields p = 0.069 β€” not genome-wide significant. The authors transparently flag this and state they "cannot completely exclude the possibility that the variant was identified by chance" . This honesty is commendable but leaves the central claim exploratory at best β€” the finding sits exactly at the boundary where winner's-curse and post-hoc narrative (HARKing risk) are most plausible.

    Biological Plausibility Is Thin

    FANCI is the Fanconi anemia complementation group I gene, essential for interstrand crosslink repair via FANCD2 monoubiquitination . A heterozygous stop-gain at Arg1285 could plausibly cause haploinsufficiency with altered DNA-damage responses β€” yet no carrier physiological, medical, or performance data were available, and the mechanism connecting partial FANCI loss to elite speed/endurance performance is entirely speculative. Notably, FANCI dysregulation is documented in cancer contexts (RAS signaling restraint via lnc-FANCI-2 ; FANCI upregulation promotes ESCC progression ), but none of this directly supports an athletic-benefit mechanism.

    What Would Change the Verdict

    • Replication in an independent top-elite cohort (any population) β€” a single failure would largely falsify the association.
    • Detection of rs121918164 in national-elite athletes or sedentary Poles at comparable rates.
    • Carrier-level physiological data: DNA-repair capacity assays (comet assay after exercise-induced oxidative stress), muscle biopsy, performance phenotyping.
    • Functional characterization: does p.Arg1285* escape nonsense-mediated decay? Is residual FANCI activity measurable?

    Bottom line: A genuinely interesting, well-verified rare-variant observation that falls short of statistical significance after multiple-testing correction, lacks any mechanistic or physiological data, and rests on three carriers. Treat as hypothesis-generating, not evidence of a "beneficial pathogenic variant."

    Author Reviews:


    Feedback:    

    Updated: September 28, 2026

     BGPT Paper Review



    Study Novelty

    60%

    First report linking a specific FANCI LoF variant to elite athleticism; rare-variant athlete-genomics is an emerging niche, but the 'antagonistic pleiotropy' framing is not conceptually new.



    Scientific Quality

    40%

    Rigorous genotyping/kinship QC and honest multiple-testing disclosure, but n=3 carriers, corrected p=0.069, no physiological data, no female athletes, no replication, and an interpretive leap from absence-in-controls to benefit.



    Study Generality

    20%

    Extremely specific single-variant, single-population, male-only finding with no mechanistic generalization beyond speculative Fanconi-pathway links.



    Study Usefulness

    30%

    Marginally useful as a replication target and as a cautionary example of rare-variant winner's-curse in sports genomics; no actionable application.



    Study Reproducibility

    40%

    Methods (GATK, Hail, TaqMan, Sanger) are clearly described and data promised on request, but raw data were not yet deposited and replication depends on rare-carrier recruitment.



    Explanatory Depth

    20%

    No mechanism is tested: no carrier phenotype data, no nonsense-mediation-decay assessment, no DNA-repair functional assays; the 'beneficial effect' is purely narrative.

     Top Data Sources ExportMCP



     DataGen



    Generated scientific data; not direct experimental measurements.

     Hypothesis Graveyard



    Direct causation: 3/101 vs 0/1,899 proves the variant drives elite status β€” rejected because Bonferroni-adjusted p=0.069 and no replication; sampling from ~443,769 LoF variants makes one such enrichment expected by chance.


    Founder effect explains clustering β€” rejected by kinship analysis (max 0.0026) and distinct birth regions.

     Science Art


    Paper Review: Possible link between the apparently pathogenic FANCI variant and beneficial effects in sports performance8 Science Art

     Science Movie



    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT